Concepedia

Publication | Open Access

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

DOIFull Paper Access

1.4K

Citations

11

References

2020

Year

Christopher P. Cannon, Richard E. Pratley, Samuel Dagogo‐Jack, James P. Mancuso, Susan Huyck, Urszula Masiukiewicz, B Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,
New England Journal of Medicine

Abstract

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).

References

YearCitations

Page 1